Table 3.

Comparison of Study Medication Adherence and Side Effects, by Study Condition

	Trazodone	Placebo	P-value
% Days took medication
By self-report (N)*	82.4 (63)	83.3 (57)	.87
From MEMSCAP data (N)	43.4 (51)	37.7 (46)	.38
Mean ± SD number of pills per day (N)*	1.98±0.7 (63)	1.98±0.6 (57)	.97
Side effects reported, % (N)†	3.06±3.3 (64)	3.67±3.5 (64)	.27
Dry mouth	37.5 (24)	23.9 (16)	.13
Morning drowsiness	31.3 (20)	48.5 (32)	.05
Weight gain	23.8 (15)	28.4 (19)	.69
Increased thirst	23.8 (15)	31.3 (21)	.43
Daytime tiredness	21.9 (14)	36.9 (24)	.08
Nervousness	18.8 (12)	19.4 (13)	1.0
Decreased interest in sex	14.8 (9)	10.6 (7)	.60
Headache	14.1 (9)	23.9 (16)	.19
Fast heartbeat	12.5 (8)	9.0 (6)	.58
Muscle aches	12.5 (8)	14.9 (10)	.80
Decreased appetite	11.1 (7)	10.5 (7)	1.0
Diarrhea	10.9 (7)	7.5 (5)	.35
Dizzy on standing	9.4 (6)	6.0 (4)	.52
Runny nose	7.8 (5)	22.7 (15)	.03
Confusion	7.8 (5)	7.5 (5)	1.0
Difficulty concentrating	6.3 (4)	14.9 (10)	.16
Uncontrolled hand movements	6.3 (4)	9.0 (6)	.74
Rash	6.3 (4)	3.0 (2)	.33
Decreased urine flow	6.3 (4)	3.0 (2)	.43
Painful/prolonged erections	5.8 (3)	0.0 (0)	.24
Nausea/vomiting	4.7 (3)	9.0 (6)	.49
Breathing trouble	4.7 (3)	1.5 (1)	.36
Blurred vision	3.2 (2)	10.5 (7)	.17
Constipation	3.1 (2)	9.0 (6)	.27
Swelling of hands/feet	1.6 (1)	6.0 (4)	.37
Mean ± SD number of side effects reported (N)†‡	3.06±3.3 (64)	3.67±3.5 (64)	.27
% Believed they were taking trazodone (N)†	79.0 (49)	48.5 (32)	.0003

^*From daily sleep log data over the first 4 weeks (total N=121)

^†From 2-week follow-up data (total N=128)

^‡Log-transformed variable